9/17/2025

Why Michael Kramer from Mott Capital Management and Reading The Markets is focused on Fed dot plot, BOJ and true valuations.

Source: SeekingAlpha

9/16/2025

Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab). Portela is a new monoclonal antibody […]

Source: Yahoo

9/16/2025

Key growth drivers include increasing pet adoption, technological advancements in veterinary healthcare, and rising animal health expenditure. The growing prevalence of pet obesity and aging pets is boosting demand for diabetes management solutions. Technological innovations improve glucose monitors and insulin pumps, crucial for pet diabetes care. The market is segmented by device type, animal type, and region, with North America holding a 41% share in 2024. Leading companies, such as Zoetis an

Source: Yahoo

9/15/2025

In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.

Source: Yahoo

9/15/2025

Zoetis Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

9/15/2025

ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.

Source: Yahoo

9/13/2025

Zoetis (ZTS) recently received a positive opinion from the European Medicines Agency's CVMP for its pain relief therapy, Portela, expected to enhance its product line for feline osteoarthritis. The company also secured a new $1.25 billion revolving credit facility to bolster its financial flexibility. These developments come amid a mixed market environment where the Nasdaq reached new highs. Despite these advancements, Zoetis' stock declined 3% last month, reflecting broader market dynamics...

Source: Yahoo

9/12/2025

PARSIPPANY, N.J., September 12, 2025--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief.

Source: Yahoo

9/12/2025

Zoetis Inc. stock outperforms competitors despite losses on the day

Source: MarketWatch

9/12/2025

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Source: Yahoo

9/12/2025

Zoetis Inc. (NYSE:ZTS) is one of the 11 Best Roth IRA Stocks to Invest in Now. Zoetis Inc. (NYSE:ZTS) strengthened its financial flexibility on August 27, 2025, by securing a new five-year, $1.25 billion senior unsecured revolving credit facility. The agreement replaces a 2022 facility that would have expired in 2027. The agreement was administered […]

Source: Yahoo

9/9/2025

Zoetis (ZTS) reached $149.79 at the closing of the latest trading day, reflecting a -1.29% change compared to its last close.

Source: Yahoo

9/9/2025

Zoetis Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

9/9/2025

Brown Advisory, an investment management company, released its “Brown Advisory Large-Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Brown Advisory Large-Cap Growth strategy has shown resilience this year amid heightened volatility, protecting investor capital during market declines and participating in the strong rebound since early April. […]

Source: Yahoo

9/9/2025

Zoetis Inc. (ZTS) is a global leader in animal health with strong organic growth, robust product innovation, and strategic M&A driving long-term revenue and earnings expansion. The company boasts exceptional dividend safety, a 13-year double-digit dividend growth streak, and a conservative payout ratio, making it ideal for dividend growth investors, explains Prakash Kolli, editor of Dividend Power.

Source: Yahoo

9/8/2025

Explore Zoetis' growth outlook, innovation pipeline, and market strategies from the 2025

Source: SeekingAlpha

9/8/2025

The key market opportunities in canine oncology diagnostics lie in adopting advanced molecular biology and imaging technologies for early cancer detection. Collaborative innovations in reagents and imaging, next-gen sequencing, liquid biopsies, and AI are reshaping precision care. Tariff adjustments prompt supply chain diversification, while strategic partnerships and vertical integration enhance value delivery. Additionally, a keen focus on regional dynamics, tailored service models, and regula

Source: Yahoo

9/6/2025

Discover top dividend growth stocks with strong returns and solid fundamentals.

Source: SeekingAlpha

9/4/2025

While Zoetis has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Source: Yahoo

9/2/2025

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Zoetis Inc. is one of them. Zoetis Inc. (NYSE:ZTS), a New Jersey–based global leader in animal health, continues to strengthen its position in the industry with medicines and vaccines for both companion animals and livestock. The company is […]

Source: Yahoo